Political interference is driving biotech investment overseas, and U.S. patients and workers will pay the price.

Both ImmunityBio IBRX and Moderna MRNA are biotech firms that depend largely on the successful commercialization of a single ...

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna's headquarters in Cambridge, Mass., in 2024. (dam Glanzman / Bloomberg via Getty Images) (Adam Glanzman) The Food and Drug ...

The EMA approved Moderna's mRNA COVID-19 and flu vaccine, but US political battles and funding cuts threaten the future of mRNA vaccine innovation. Talha Burki reports.

Since being sworn in as Health and Human Services (HHS) secretary, Robert F. Kennedy Jr has repeatedly tried to undermine public trust in vaccines. His agency recently took steps to slow down the ...

Continue » Moderna's shares could soar as it advances its mRNA platform. Compared to older vaccines, those of the mRNA ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

They aren't just "pandemic stocks." ...

If you are wondering whether Moderna's share price really reflects what the business is worth today, you are not alone. That ...